Fezolinetant (Veoza™). HTA ID: 24005

Assessment Status Pre submission consultation scheduled
HTA ID 24005
Drug Fezolinetant
Brand Veoza™
Indication Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.
Assessment Process
Rapid review commissioned 09/02/2024
Rapid review completed 12/03/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fezolinetant compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 08/04/2024